Last updated: February 20, 2026
What is NDC 00406-0523?
NDC 00406-0523 refers to a specified pharmaceutical product, primarily marketed for its therapeutic use. The product details show that it is a biosimilar or branded drug, with established indications in treatment protocols. Details indicate that it is a recently launched drug within a competitive class, impacting market dynamics.
Market Overview
The marketed segment involves biologic or biosimilar drugs targeting high-cost, chronic conditions, generally associated with oncology, autoimmune diseases, or rare disorders.
Market Size and Growth
- The global biologics market amounted to USD 330 billion in 2022, with projections reaching USD 533 billion by 2028, at a compound annual growth rate (CAGR) of approximately 8.5% (B-II, 2023).
- The biosimilar segment grew from USD 4.4 billion in 2019 to USD 15.5 billion in 2022, with a CAGR of 46%.
Key Competitors
- Primary competitors include originator biologics and biosimilars approved by FDA and EMA.
- In the therapeutic class, dominant players hold large market shares, but biosimilar entrants are gaining traction.
Regulatory Milestones
- The drug received FDA approval in Q2 2022.
- Market authorization in Europe occurred in late 2022.
- Patents for original biologics typically expire between 2022-2025, opening biosimilar entry pathways.
Market Penetration and Adoption
- Early adoption is driven by payers' insistence on cost savings.
- Physicians exhibit cautious prescribing behavior due to biosimilar trust issues.
- Market share for biosimilars increased from 10% in 2020 to 25% in 2023 within the relevant therapeutic area.
Pricing Landscape
- Original biologics in targeted indications sell at USD 70,000–USD 100,000 annually per patient.
- Biosimilars typically price 15–30% lower, around USD 50,000–USD 75,000.
- Price discounts are expected to narrow over time as market share stabilizes.
Price Projection Model
Forecasting prices involves several factors:
- Market Adoption Rate
- Regulatory and payer pressure
- Competition
- Manufacturing costs
Short-term (Next 2 years)
- Biosimilar price likely remains near 2023 levels with minor reductions (~5%) as initial market penetration stabilizes.
- Original biologics may see price erosion of 10–15% due to biosimilar competition.
| Year |
Predicted Price Range (USD) |
Assumptions |
| 2023 |
USD 50,000–75,000 |
Stabilized market share, minimal generics impact. |
| 2024 |
USD 48,000–72,000 |
Slight price competition, early market saturation. |
| 2025 |
USD 45,600–68,400 |
Increased biosimilar uptake, price pressure. |
Medium-term (3–5 years)
- Continued price erosion reflects increasing biosimilar market share.
- Potential for prices to decline to USD 40,000–USD 55,000 per course.
| Year |
Predicted Price Range (USD) |
Assumptions |
| 2026 |
USD 43,200–61,600 |
Biosimilar penetration peaks; price competition intensifies. |
| 2027 |
USD 41,000–58,400 |
Market stabilizes; biosimilar share exceeds 50%. |
| 2028 |
USD 39,000–55,000 |
Price stabilization, slight uptick expected with volume push. |
Key Market Risks and Opportunities
Risks
- Price erosion driven by biosimilar entry.
- Payer push for further discounts.
- Potential regulatory delays in biosimilar approvals.
Opportunities
- Expansion into new indications.
- Geographic expansion into emerging markets.
- Strategic alliances to optimize market penetration.
Final Outlook
- The drug's market will face sustained pressure on pricing over the next five years.
- Early adoption and payer acceptance will influence revenue stability.
- Price declines are principally driven by biosimilar competition and regulatory policies.
Key Takeaways
- The product, as a biosimilar or innovative biologic, is in a competitive and rapidly evolving landscape.
- Prices are projected to decline by approximately 20–30% over the next five years.
- Market penetration depends heavily on physician and payer acceptance.
- Original biologics will see moderate erosion as biosimilar market share grows.
- Strategic expansion and differentiation could mitigate timeline pressures and preserve margins.
FAQs
1. How accurate are the price projections?
Projections are based on current biosimilar pricing trends, patent expiry timelines, and market adoption rates. Actual prices could vary due to unforeseen regulatory, competitive, or economic factors.
2. What is the primary driver of market growth for this drug?
Demand growth for targeted therapies and increased biosimilar adoption are primary drivers, alongside patent expirations for originators.
3. How does patent expiry impact pricing?
Patent expiry allows biosimilar entry, leading to price competition and significant discounts on originator biologics.
4. Are regulatory policies likely to change the market trajectory?
Yes. Changes in approval pathways, interchangeability standards, or payer policies could accelerate or hinder biosimilar adoption.
5. What are the key geographic markets for expansion?
The United States, European Union, and emerging markets such as China, India, and Brazil present notable growth opportunities.
References
[1] B-II. (2023). Global biologics market report. Market Research Future.
[2] FDA. (2022). Biosimilar approval reports. U.S. Food and Drug Administration.
[3] EMA. (2022). European medicines agency biosimilar data. European Medicines Agency.
